

PU4959USw

Remarks

Currently Claims 1-6, 9-17 and 19-20 are pending. Claims 1 and 20 are amended herein.

Applicants acknowledge with appreciation the time and courtesies extended by the Examiner during the telephonic interview of 14 July 2006.

The amendment to claim 1 overcomes the new rejection recited in the Advisory Action, for inclusion of non-elected subject matter.

The amendment to claim 20 is the same amendment as was presented in the Response filed 22 Jun 2006. As indicated in the Advisory Action, the amendment obviates the rejection of claim 20 based on section 112, second paragraph and entry of this amendment is therefore proper.

Applicants understand the Examiner to have agreed that the amendments to claims 1 and 20 will be entered inasmuch as they narrow the issues for appeal by overcoming two outstanding rejections. Applicants respectfully maintain the traversal of the remaining rejections of claims 14 and 19 on the grounds stated in the response filed 22 Jun 2006. A Notice of Appeal will be timely filed with respect to those rejections. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 14 July, 2006
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988